{"id":169900,"date":"2024-07-23T02:43:36","date_gmt":"2024-07-23T06:43:36","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/arcutis-to-host-zoryve-roflumilast-cream-0-15-fda-approval-call-with-kol\/"},"modified":"2024-08-18T11:48:48","modified_gmt":"2024-08-18T15:48:48","slug":"arcutis-to-host-zoryve-roflumilast-cream-0-15-fda-approval-call-with-kol","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arcutis-to-host-zoryve-roflumilast-cream-0-15-fda-approval-call-with-kol.php","title":{"rendered":"Arcutis to Host ZORYVE\u00ae (Roflumilast) Cream 0.15% FDA Approval Call With KOL"},"content":{"rendered":"<p><![CDATA[WESTLAKE VILLAGE, Calif., July  22, 2024  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for individuals with mild to moderate atopic dermatitis (AD). The event will highlight the differentiating features of and commercialization plans for ZORYVE\u00ae (roflumilast) cream 0.15%, which recently received FDA approval for the treatment of AD in adults and children down to age 6.]]><\/p>\n<p>Visit link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/22\/2916478\/0\/en\/Arcutis-to-Host-ZORYVE-Roflumilast-Cream-0-15-FDA-Approval-Call-With-KOL.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Arcutis to Host ZORYVE\u00ae (Roflumilast) Cream 0.15% FDA Approval Call With KOL\">Arcutis to Host ZORYVE\u00ae (Roflumilast) Cream 0.15% FDA Approval Call With KOL<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Visit link: Arcutis to Host ZORYVE\u00ae (Roflumilast) Cream 0.15% FDA Approval Call With KOL <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arcutis-to-host-zoryve-roflumilast-cream-0-15-fda-approval-call-with-kol.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169900","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169900"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169900"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169900\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}